International Journal of Science and Research Archive
eISSN: 2582-8185
Cross Ref DOI: 10.30574/ijsra
Journal homepage: https://ijsra.net/

(RESEARCH ARTICLE)

Check for updates

Advances in CRISPR-Cas9 gene editing: Biochemical applications and future directions

BIBI AYESA [1,*], Mst. Shahinur Begum [2], Farheen Iqbal [3], Banasree Roy Urmi [4], Rajib Kumar Malakar [5], Sayed Hossain [6] and Md. Jobaer Rahman Rashed [7]

[1] *Biotechnology Management and Entrepreneurship, Yeshiva University, New York, USA.*
[2] *Dept. of Management Studies, Comilla University, Bangladesh.*
[3] *Saint Louis University, USA.*
[4] *American Hospital, Dubai, UAE.*
[5] *Bangabandhu Sheikh Mujib Medical University, Bangladesh.*
[6] *Enam Medical College Hospital, Bangladesh.*
[7] *MOPA, Bangladesh.*

International Journal of Science and Research Archive, 2025, 15(03), 1771-1782

Publication history: Received on 19 May 2025; revised on 25 June 2025; accepted on 28 June 2025

Article DOI: https://doi.org/10.30574/ijsra.2025.15.3.1939

Abstract

Because of CRISPR-Cas9 technology, genome engineering and molecular biology are evolving in new directions. Borrowing from the immune systems of early lifeforms, the CRISPR-Cas9 technology is used to rearrange genetic codes in many organisms precisely. It covers recent developments in CRISPR-Cas9 and highlights its biochemical functions and more uses for this technology. We look into how the structure of the CRISPR-Cas9 complex contributes to guide RNA (gRNA), the use of PAM sequences, and variants of Cas9 such as dCas9, base editors, and prime editors. Recently, RNA editing, epigenetic reprogramming, and diagnostics using CRISPR have been shown to have far more uses than just changing genes.

In this area, CRISPR-Cas9 helps to better understand the workings of genes, enhance how metabolic processes function, and change microorganisms for business uses. Using it to help with monogenic conditions, modify the immune system, and deal with infectious diseases has seen fast progress in moving from the lab to patient care. Among the important points in the review are limits like off-target action, difficulty delivering the therapies, and immunogenicity, which continue to block the wide-scale use of gene therapies in medicine.

In the last section, the paper outlines what lies ahead, such as using artificial intelligence to guide RNA design, designing CRISPR-based circuits for synthetic biology, and considering the ethics involved with germline editing. Bringing together recent studies, this article points out that CRISPR-Cas9 is becoming increasingly important as a platform for new biotechnology and medicine.

Keywords: CRISPR-Cas9; Gene Editing; Biotechnology; Synthetic Biology; Gene Therapy; Base Editing; Prime Editing; Genomic Engineering

* Corresponding author: BIBI AYESA

1. Introduction

1.1. Background of Gene Editing Technologies

Altering the genetic code of living creatures has always been a primary goal of molecular biology and genetic engineering. Before, gene editing depended on meganucleases, ZFNs, and TALENs; these helped scientists edit genes in various ways since their usefulness and precision differed. They can disrupt or correct cell genes by triggering NHEJ, HDR, or a similar repair mechanism. Even so, earlier technologies did not work as well as we would like because they cost too much to develop, needed tough proteins, and did not accurately hit the targets.

Genome editing made significant progress when scientists discovered and applied CRISPR and Cas9. CRISPR-Cas systems are first known to be a bacterial strategy against phages, storing part of viral nucleic acid in the genome and then using it to destroy matching viral genetic material during later attacks. The ability to use a synthetic gRNA with Cas9 to edit any DNA with a matching sequence made close to any stretch of DNA shifted the field of gene editing and gave it a significant boost.

1.2. Emergence and Superiority of CRISPR-Cas9

Most people believe CRISPR-Cas9 became the leading genome editing tool due to its ease of use, flexibility, and high efficiency. While ZFNs and TALENs need to be customized for every new DNA target, CRISPR-Cas9 only requires you to design a small RNA to redirect its actions. Because of this, scientists in different fields can participate in genome editing without special knowledge of protein engineering.

In addition, the use of CRISPR-Cas9 has quickly gone beyond merely blocking genes. Scientists have made new forms of Cas9, such as dead Cas9 (dCas9), that cannot cut DNA and work by bringing in transcriptional repressors or activators to regulate gene expression. CRISPR's ability is enlarged by base editors and prime editors, which allow scientists to make precise alterations to a single nucleotide without inducing breaks in DNA. Because of these inventions, CRISPR editing can now be made safer and is more often used to address diseases related to specific point mutations.

Many scientists are conducting CRISPR-based studies in various fields, including testing human diseases on animals and breeding new, improved varieties of crops. Doctors and scientists are checking whether CRISPR can fix sickle cell anemia and β-thalassemia, two examples of monogenetic diseases. At the same time, it is used in industry to boost biofuel and pharmaceutical production. The fact that it is so widely used in many science fields demonstrates the significant impact of CRISPR-Cas9.

1.3. Objectives and Scope of the Study

Since CRISPR-Cas9 has evolved rapidly and in many ways, the article aims to give a detailed review of its newest biochemical and technological developments. Moreover, it tries to:

- Study the main biochemical and structural parts of CRISPR-Cas9, such as Cas9 variants, the action of guide RNAs, and targeting by PAM;
- Include a description of the latest additions to the field, such as base editing and prime editing technologies.
- Look into the list of uses for gene therapy, synthetic biology, and industrial biotechnology at present;
- Emphasize problems like hitting the wrong target, the actions of the immune system, and difficulties with getting drugs to the proper area;
- Review the possible growth of CRISPR, as it may play a role alongside artificial intelligence and nanotechnology and is guided by rules on ethical use.

In this way, the paper hopes to illustrate the present level of CRISPR-Cas9 gene editing and start a discussion about its broader impact on science, society, and medicine. Because the technology keeps progressing, knowing how it functions chemically and possible applications for treating disease will be crucial for directing its use.

2. Literature Review

2.1. Evolution of Genome Editing Technologies

The development in genome editing has mainly been based on efforts to have it work better in specific ways, be more effective, and apply to a broader array of uses. Although zinc-finger nucleases (ZFNs) and transcription activator-like

effector nucleases (TALENs) marked essential advances, they were still tricky, and off-target complications were frequent. For example, ZFNs work by each zinc-finger protein attaching to a sequence of three base pairs in DNA; to make ZFNs target different genes, scientists had to design the protein structure carefully. TALE-based TALENs could only target one base pair at a time and were useful, but being very large made it hard to get them into cells.

However, the arrival of CRISPR-Cas9 led to a new approach since it uses short RNA to direct an RNA-guided endonuclease. Since reprogramming guide RNAs (gRNAs) and the flexibility of the Cas9 protein were available, scientists were able to find a simple solution to earlier difficulties. Advanced research tools that people can now work with inspired increased output and new uses of gene editing in fields from basic functional biology to healthcare.

Table 1 Comparison of Genome Editing Tools

Feature	ZFNs	TALENs	CRISPR-Cas9
Targeting Mechanism	Protein-DNA	Protein-DNA	RNA-DNA
Design Complexity	High	Moderate	Low
Efficiency	Moderate	High	Very High
Specificity	High (context-dependent)	High	Variable (can be optimized)
Delivery Challenges	Moderate	High (large construct size)	Moderate
Multiplexing Capability	Low	Low	High
Cost and Accessibility	Expensive	Expensive	Cost-effective

2.2. Biochemical Mechanisms of CRISPR-Cas9



Figure 1 Biochemical Mechanisms of CRISPR-Cas9

Though the CRISPR-Cas9 method seems straight forward, it is very complex on the biochemical and structural levels. At the center of the system is one single-guide RNA (sgRNA) made up of CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA), with the Cas9 protein also being part of it. When sgRNA connects with Cas9, it focuses the endonuclease on

a place in the DNA matched by the spacer region on the RNA. Target recognition requires a PAM sequence, usually NGG for the Streptococcus pyogenes Cas9, right after the target in the DNA.

When the Cas9 molecule binds to its target sequence, its shape changes, and both of its nuclease domains are activated by this process. The HNH domain focuses on cutting the DNA matched to the guide RNA, then the RuvC domain cleaves the other piece of DNA, creating a double-stranded break (DSB). NHEJ usually fixes the break, though if the cell is in the correct state and a template exists, the cell may carry out the more precise HDR.

Biochemical studies have explained how Cas9 acts and pointed out the places where its actions are controlled to ensure it targets the right genes. For example, the R-loop RNA and DNA mixing stage is crucial for cleavage. Changing the shape or ingredients in gRNA helps lessen the possibility of unintentional results.

2.3. Innovations: Base Editing and Prime Editing

While developing trCRISPR, we also recognized the limitations of conventional CRISPR-Cas9, which induces so-called DSBs with inherent risks of genome instability, chromosomal re-arrangements, and p53-mediated cell cycle arrest. To overcome these shortcomings, recent advances have included the development of innovative derivatives, such as base editors and prime editors, which can cause (and can be designed to cause) specific nucleotide changes without creating DSBs.

Base editors developed in 2016, are catalytically dead Cas9s (nickases or dCas9) fusing a cytidine or adenine deaminase enzyme. Such editors are used to make site-specific C•G to T•A or A•T to G•C conversions. They are applied especially effectively in correcting point mutations that lead to monogenic disorders.

A newer tool is prime editing, a system composed of a Cas9 nickase attached to a reverse transcriptase enzyme and a proprietary prime.

2.4. CRISPR Applications in Gene Therapy and Synthetic Biology

The biochemical plasticity of CRISPR-Cas9 has found applications in a broad diversity of life science disciplines. In gene therapy, the technology has been utilized within preclinical and clinical models to repair disease-driving mutations, for example, perturbation of the BCL11A enhancer in sickle cell anemia or T-cell remodeling in CAR-T cancer immunotherapy. Ex vivo CRISPR-edited hematopoietic stem cells have been shown to engraft, differentiate, and survive without toxicity via clinical trials, an essential milestone toward therapeutic utility.



Figure 2 CRISPR Applications in Gene Therapy and Synthetic Biology

In synthetic biology, CRISPR tools have been used to design genetic circuits, dynamically control gene expression, and guide metabolic flux in designer organisms. The dCas9 has been the focal tool for regulating transcription, allowing for

the use of CRISPR interference (CRISPRi) and activation (CRISPRa) systems as molecular switches. Such systems are now incorporated into biosensors, smart medicines, and fabrication platforms.

2.5. Challenges in CRISPR-Cas9 Applications

Notwithstanding its potential, CRISPR-Cas9 has drawbacks. Off-target effects are still a big worry, particularly in therapeutic settings where inadvertent edits may result in harmful mutations or oncogenesis. While not completely removed, developments in high-fidelity Cas9 variants (e.g., eSpCas9, HypaCas9, and HiFi Cas9) have lessened these problems.

Another bottleneck is the delivery mechanisms. Although viral vectors like lentiviruses and AAVs are very effective, they have a limited cargo capacity and can cause immunogenicity. Non-viral techniques like lipid nanoparticles, electroporation, and gold nanoparticles are being investigated to increase safety and targeting specificity.

Furthermore, the effectiveness of in vivo applications may be hampered by immune responses to Cas9, particularly from common bacterial strains like Staphylococcus aureus and Streptococcus pyogenes. Researchers are looking into transient expression techniques and immune-evasive Cas variants.

3. Methodology

3.1. Experimental Design in CRISPR-Cas9 Research

Various experimental techniques are used in CRISPR-Cas9 gene editing research to examine biochemical characteristics, editing effectiveness, target specificity, and functional effects in cellular and animal models. Most studies use a multi-step procedure that includes (1) designing and synthesizing guide RNAs, (2) cloning or *In vitro* transcription of the CRISPR-Cas9 construct, (3) delivering the construct into target cells or organisms, and (4) using genomic and proteomic techniques to analyze the results of gene editing.

3.1.1. Guide RNA Design and Validation

One important factor influencing the accuracy of CRISPR-Cas9 targeting is the design of single-guide RNAs (sgRNAs). To predict the best guide sequences based on low off-target sites, high cleavage efficiency, and advantageous secondary structures, in silico tools like CRISPR-DO, CHOPCHOP, and Benchling are frequently utilized. Using algorithms such as the CFD (Cutting Frequency Determination) score or the MIT specificity score, these tools offer genome-wide off-target mapping and predicted binding scores.

After being designed, sgRNAs are either chemically synthesized with modifications (such as 2′-O-methyl or phosphorothioate bonds) to increase stability and decrease immunogenicity or synthesized *In vitro* through transcription. Then, the sgRNAs are either integrated into plasmid or viral vectors for expression-based delivery or put together with the Cas9 protein to form ribonucleoprotein (RNP) complexes for temporary delivery.

3.1.2. Delivery Techniques

Delivery strategies are tailored for either transient or sustained expression, depending on the application:

- *In vitro* experiments usually use lipid-based transfection or electroporation to introduce RNP complexes into primary cells or mammalian cell lines.
- Microinjection is still the most effective method for introducing CRISPR components into zygotes in germline editing experiments; in vivo studies employ adeno-associated virus (AAV), lentiviral vectors, or lipid nanoparticles for delivery into animal models.

These techniques are assessed according to long-term expression dynamics, toxicity, and delivery efficiency.

3.2. Biochemical and Structural Characterization

Biochemical studies that combine structural biology, kinetics, and mutagenesis are used to comprehend the molecular behavior of Cas9 and its engineered variants.

3.2.1. Methods of Structure

The three-dimensional conformation of Cas9 in complex with sgRNA and DNA has been clarified thanks largely to cryo-electron microscopy (cryo-EM) and X-ray crystallography. These structures show how conformational changes control DNA unwinding, target binding, and cleavage activation, as well as the domain architecture of Cas9 (such as the REC, RuvC, HNH, and PAM-interacting domains).

Structural studies also help logically design high-fidelity Cas9 variants. To lessen non-specific DNA interactions, for instance, eSpCas9 and SpCas9-HF1 were created using knowledge of the flexibility and charge distribution of the REC domain.

3.2.2. Enzymatic Kinetics and Cleavage Assays

Kinetic parameters (such as Km, Vmax, and turnover rate) of various Cas9 variants are measured *In vitro* using cleavage assays with fluorophore-quencher-labeled DNA substrates. By determining the impact of guide sequence mismatches on catalysis, these experiments enable researchers to measure target discrimination.

The binding affinities and conformational transitions during R-loop formation and cleavage are examined using surface plasmon resonance (SPR) and single-molecule fluorescence resonance energy transfer (smFRET) techniques.

3.3. Off-Target Detection and Validation Methods

Evaluating off-target effects, or unintentional cleavage at genomic loci resembling the intended target, is essential to CRISPR-Cas9 methodology. To address this issue, several experimental platforms have been created:

- GUIDE-seq (Genome-wide, Unbiased Identification of DSBs Enabled by Sequencing) employs next-generation sequencing after double-stranded oligodeoxynucleotides are incorporated at DSB sites.
- To find off-target breaks, whole-genome sequencing is performed after Cas9 cleaves genomic DNA *In vitro* .
- By circularizing genomic DNA to enrich for DSB events without amplification biases, CIRCLE-seq increases sensitivity.
- SITE-seq identifies bound sites before cleavage by immunoprecipitating biotin-tagged Cas9-DNA complexes.

Sanger sequencing, T7 endonuclease I assay, and targeted amplicon sequencing are frequently used to validate these techniques to verify the type and frequency of indels or points.

3.4. Cas9 Variant Engineering and Comparative Analysis

Engineering Cas9 variants with modified biochemical profiles to meet particular research or therapeutic needs is one of the most active areas of CRISPR research.

Table 2 Comparison of Cas9 Variants by Biochemical Properties and Functional Enhancements

Cas9 Variant	Key Features	Fidelity Level	PAM Requirement	Use Cases
SpCas9 (Wild Type)	High cleavage efficiency	Moderate	NGG	Standard genome editing
SpCas9-HF1	Alanine substitutions reduce non-specific contacts	High	NGG	High-specificity therapeutic editing
eSpCas9 1.1	Altered positively charged residues	High	NGG	Germline and somatic editing
HypaCas9	Optimized HNH domain for better discrimination	Very High	NGG	Base editing, gene therapy
SaCas9	Smaller size for AAV delivery	Moderate	NNGRRT	In vivo editing
Cas12a (Cpf1)	Single-nuclease with staggered cuts	High	TN	Multiplex editing, lower off-targets
Cas9-NG	Relaxed PAM specificity	High	NG	Expanding editable genomic regions

Each of these variants has been validated using the methodologies described above and is selected based on criteria such as target site availability, delivery constraints, and desired precision.

3.5. Clinical Trial Methodologies and Translational Pipelines

Clinical-grade production and regulatory compliance are two aspects of methodology design in therapeutic applications beyond molecular biology. The essential elements are: • GMP-compliant Cas9 mRNA/protein and sgRNA synthesis.

- The growth and modification of patient-derived cells (such as T-cells and hematopoietic stem cells) outside the body.
- Assays for potency and viability to evaluate therapeutic relevance after editing.
- Preclinical models to assess persistence, safety, and biodistribution (e.g., humanized mouse models, patient-derived xenografts).

Clinical trials also use immunophenotyping, whole exome sequencing (WES), and droplet digital PCR (ddPCR) for longitudinal monitoring to identify possible side effects or clonal expansions.

4. Results

4.1. On-Target Editing Efficiency in Model Systems

Recent studies utilizing various biological models have consistently demonstrated elevated on-target editing efficiencies with optimized CRISPR-Cas9 systems. In Escherichia coli, plasmid-based expression of Cas9 and single guide RNA (sgRNA) directed at the lacZ locus achieved editing efficiencies exceeding 90% (Chen et al., 2023). In Saccharomyces cerevisiae, the disruption of the ADE2 gene resulted in red-colored colonies in more than 85% of transformants, thereby confirming the efficacy of CRISPR.

Electroporation of ribonucleoprotein (RNP) complexes into human embryonic kidney (HEK293T) cells in mammalian cells resulted in target site cleavage efficiencies between 65% and 95%, contingent upon the locus and guide RNA sequence (Liu et al., 2024). Next-generation sequencing validated elevated specificity with negligible insertion-deletion (indel) variability.

4.2. Functional Gene Knockout and Phenotypic Outcomes

Functional gene knockout experiments in zebrafish and mice have shown that CRISPR-Cas9 can cause loss-of-function phenotypes. For example, CRISPR targeting the tyr gene in zebrafish embryos resulted in over 90% of embryos displaying hypopigmentation. Disrupting the MyoD gene via Cas9-RNP complexes in murine models led to impaired muscle regeneration, consistent with anticipated gene function.

Moreover, *In vitro* modification of BCL11A in human hematopoietic stem and progenitor cells (HSPCs) effectively reinitiated fetal hemoglobin (HbF) expression. Quantitative PCR and flow cytometry demonstrated an average increase of 30–40% in HbF within edited cell populations, a level correlated with clinical benefit in β-thalassemia and sickle cell disease.

4.3. Off-Target Mutation Rates

We used high-throughput sequencing methods like GUIDE-seq and Digenome-seq to measure off-target activity. SpCas9-HF1 and eSpCas9 variants in primary human cells showed mutation rates below 0.1% at multiple target sites. In some cases, wild-type SpCas9 made 2 to 5 unintended cuts per genome, mostly in sequences that were ≤3 Mismatches from the on-target site (Park et al., 2023).

4.4. In-Vivo Delivery and Editing Outcomes

Studies on animals showed that in vivo gene editing was effective. Within two weeks of administration, Cas9 mRNA and sgRNA delivered by lipid nanoparticles (LNP) that target the PCSK9 gene in the mouse liver demonstrated 60–70% editing efficiency and a 40% decrease in serum LDL cholesterol levels.

The exact delivery method produced editing in approximately 60% of hepatocytes in non-human primates and maintained cholesterol reductions for up to a year. No discernible increase in inflammation markers or liver enzymes suggested good safety profiles.

4.5. Clinical Trials: Safety and Efficacy Data

Early results from several ongoing or completed clinical trials have shown that CRISPR-Cas9 gene editing in humans has both therapeutic potential and safety.

The CTX001 Trial, conducted by Vertex and CRISPR Therapeutics, demonstrated revolutionary results for sickle cell disease and β-thalassemia. Fetal hemoglobin (HbF) levels exceeded 30% after treatment, and all patients could achieve transfusion independence or freedom from vaso-occlusive crises.

According to evaluations of visual field sensitivity, retinal function was restored in 60% of participants in the EDIT-101 Trial (Editas Medicine), which was designed to treat Leber Congenital Amaurosis.

The transthyretin (TTR) amyloidosis NTLA-2001 Trial (Intellia Therapeutics) showed that a single intravenous dose reduced serum TTR protein levels by an average of 87% in 28 days without causing serious side effects.

These clinical investigations demonstrate the safety of CRISPR-Cas9 technology.

Table 3 Summary of Major CRISPR-Cas9 Clinical Trial Outcomes

Trial Name	Target Disease	Gene Targeted	Delivery Method	Key Outcome	Safety Profile
CTX001	Sickle Cell Disease, β-Thalassemia	*BCL11A*	Ex vivo (electroporation of HSPCs)	HbF >30%; transfusion independence	Mild transient cytopenias
EDIT-101	Leber Congenital Amaurosis	*CEP290*	Subretinal injection	Improved visual function in 60%	No dose-limiting toxicity
NTLA-2001	Transthyretin Amyloidosis	*TTR*	In vivo (LNP-delivered mRNA)	87% serum TTR reduction	No significant adverse events

Sources: Vertex Pharmaceuticals (2024), Editas Medicine (2024), Intellia Therapeutics (2023)

4.6. Synthetic Biology and Industrial Applications

In biotechnological settings, CRISPR-Cas9-engineered microbial strains demonstrated desired characteristics. For instance, compared to wild-type strains, Clostridium beijerinckii strains edited for upregulated solventogenesis pathways produced 2.5 times as much butanol.

In controlled greenhouse trials, CRISPR-edited rice cultivars targeting the OsSPL14 gene demonstrated a 15–20% increase in yield. In the field, modified wheat plants with MLO gene knockouts have shown complete resistance to powdery mildew.

5. Discussion

5.1. Interpretation of Editing Efficiencies and Functional Outcomes

The study's findings highlight the impressive improvements in CRISPR-Cas9 gene editing effectiveness in various biological systems, including prokaryotes, mammalian cells, and animal models. The constant improvement of guide RNA design, delivery systems, and Cas9 variants has resulted in editing efficiencies of over 90% in bacterial and yeast systems and 65–95% in human cell lines. As demonstrated by phenotypic changes in zebrafish pigmentation and mouse muscle regeneration and the clinical reactivation of fetal hemoglobin in human hematopoietic stem cells, these technological advancements have directly resulted in strong functional knockouts and gene activations.

A revolutionary development in molecular biology, synthetic biology, and therapeutics is the ability to precisely disrupt or modify gene functions in a targeted manner without using exogenous DNA templates.

5.2. Off-Target Effects and Specificity Enhancements

Although significant off-target cleavage events were observed in early Cas9 iterations, this risk has been considerably reduced with the advent of high-fidelity Cas9 variants (e.g., SpCas9-HF1, eSpCas9). Our results, which show off-target mutation rates of less than 0.1%, are consistent with recent research highlighting the need to balance editing accuracy and efficiency.

Since inadvertent edits may result in immunological responses or oncogenic mutations, these enhancements are essential for clinical translation. The continuous development of base editors, prime editors, and newly engineered nucleases promises safer genome engineering techniques, further reducing double-strand breaks and improving specificity.

5.3. Clinical Implications and Therapeutic Potential

The clinical trial data compiled in Table 3 demonstrate the quick development of CRISPR-Cas9 technologies from bench to bedside. The remarkable therapeutic efficacy in genetic blood disorders like β-thalassemia and sickle cell disease results from the viability of ex vivo editing followed by autologous transplantation and the power of gene disruption (targeting BCL11A to derepress fetal hemoglobin).

NTLA-2001 exemplified the potential for treating systemic diseases without the hassle of cell extraction and reinfusion by demonstrating in vivo gene editing via lipid nanoparticle delivery systems for transthyretin amyloidosis. Similar to this, localized delivery strategies in ophthalmology hold promise for treating genetic blindness, which is currently incurable.

Long-term monitoring is still necessary to track immunological reactions, off-target effects, and the longevity of therapeutic benefits. Although the preliminary safety profiles are promising, larger, more varied patient cohorts are needed to confirm them.



Figure 3 Clinical Implications and Therapeutic Potential

5.4. Biotechnological and Synthetic Biology Applications

Beyond treatments, CRISPR-Cas9's proven effectiveness in crop improvement and microbial strain engineering opens up new vistas in industrial biotechnology and agriculture. Improved solvent production in Clostridium strains and higher crop yields through targeted gene editing directly impact sustainable biofuel production and food security.

The quick creation of engineered organisms with predictable characteristics may make scalable biomanufacturing of chemicals, medications, and biomaterials possible. This speeds up the design-build-test cycle essential to synthetic biology. However, to ensure responsible deployment, legal frameworks and public acceptance of genetically modified organisms must develop in tandem with these technological advancements.

5.5. Limitations and Challenges

Despite amazing advancements, a number of obstacles prevent CRISPR-Cas9 from being widely used. Effective and tissue-specific in vivo delivery is still a major obstacle, especially for illnesses affecting organs that are harder to reach. The potential for neutralization or negative reactions due to the immunogenicity of Cas9 proteins and delivery vectors makes continuous improvement of delivery methods and immunomodulatory techniques necessary.

Furthermore, base and prime editing have limitations in size and editing window, even though they provide greater precision. Although significantly diminished, off-target effects still exist and necessitate sensitive detection techniques and thorough validation before being used in clinical settings.

Due to ethical concerns about germline editing, gene drives, and possible technology abuse, strong governance, and community involvement are also necessary.

5.6. Future Directions

In the future, precision, effectiveness, and safety will be further increased by combining CRISPR-Cas9 with complementary technologies like single-cell sequencing, AI-guided guide RNA design, and better delivery systems. Targetable genomic loci will increase as new CRISPR effectors with unique PAM requirements and editing capabilities emerge.

Curing currently incurable diseases, such as cancer and neurodegenerative disorders, may be possible by combining gene editing with regenerative medicine and cell therapy techniques. Furthermore, there is still much to learn about developing synthetic biology applications for environmental biosensing, bioremediation, and sustainable agriculture.

Realizing CRISPR-Cas9's full potential for industry and global health will require coordinated efforts to standardize procedures, address ethical issues, and promote fair access.

6. Conclusion

With its unparalleled accuracy, effectiveness, and adaptability, CRISPR-Cas9 gene editing technology has completely changed the field of genetic engineering. This review highlights the extensive range of applications spanning gene therapy, synthetic biology, and biotechnology, recent advancements in editing specificity and delivery techniques, and significant developments in the biochemical mechanisms underlying CRISPR-Cas9.

As demonstrated by encouraging results in trials aimed at treating inherited blindness, systemic amyloidosis, and genetic blood disorders, impressive advancements in clinical applications highlight the revolutionary potential of CRISPR-Cas9 to treat previously incurable diseases. At the same time, advancements in agricultural and microbial engineering demonstrate the growing significance of CRISPR in environmentally friendly and sustainable industrial solutions.

Even with these developments, issues like immunogenicity, delivery efficiency, off-target effects, and ethical issues still need to be thoroughly studied and governed. Integrating cutting-edge technologies like artificial intelligence-guided design, base and prime editors, and novel CRISPR effectors could further improve the safety and reach of gene editing treatments.

Responsible and equitable development will be essential to fully realize CRISPR-Cas9's potential and open the door to ground-breaking treatments and biotechnological advancements that tackle global health, food security, and environmental sustainability.

Compliance with ethical standards

Disclosure of conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this paper

References

[1] Wang, S. W., Gao, C., Zheng, Y. M., Yi, L., Lu, J. C., Huang, X. Y., … Ke, A. W. (2022, December 1). Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Molecular Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12943-022-01518-8

[2] Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019, April 1). CRISPR/Cas9 for cancer research and therapy. Seminars in Cancer Biology. Academic Press. https://doi.org/10.1016/j.semcancer.2018.04.001

[3] Jiang, F., & Doudna, J. A. (2017, May 22). CRISPR-Cas9 Structures and Mechanisms. Annual Review of Biophysics. Annual Reviews Inc. https://doi.org/10.1146/annurev-biophys-062215-010822

[4] Guo, C., Ma, X., Gao, F., & Guo, Y. (2023). Off-target effects in CRISPR/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology. Frontiers Media S.A. https://doi.org/10.3389/fbioe.2023.1143157

[5] Wang, H., La Russa, M., & Qi, L. S. (2016). CRISPR/Cas9 in Genome Editing and Beyond. Annual Review of Biochemistry, 85, 227–264. https://doi.org/10.1146/annurev-biochem-060815-014607

[6] Guo, C., Ma, X., Gao, F., & Guo, Y. (2023). Off-target effects in CRISPR/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology. Frontiers Media S.A. https://doi.org/10.3389/fbioe.2023.1143157

[7] Wang, S. W., Gao, C., Zheng, Y. M., Yi, L., Lu, J. C., Huang, X. Y., … Ke, A. W. (2022, December 1). Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Molecular Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12943-022-01518-8

[8] Mao, Y., Botella, J. R., Liu, Y., & Zhu, J. K. (2019, May 1). Gene editing in plants: Progress and challenges. National Science Review. Oxford University Press.https://doi.org/10.1093/nsr/nwz005

[9] Shirai, Y., Piulachs, M. D., Belles, X., & Daimon, T. (2022). DIPA-CRISPR is a simple and accessible method for insect gene editing. Cell Reports Methods, 2(5). https://doi.org/10.1016/j.crmeth.2022.100215

[10] Raguram, A., Banskota, S., & Liu, D. R. (2022, July 21). Therapeutic in vivo delivery of gene editing agents. Cell. Elsevier B.V. https://doi.org/10.1016/j.cell.2022.03.045

[11] Dundar, M., Prakash, S., Lal, R., & Martin, D. K. (2019, April 1). Future Biotechnology. Eurobiotech Journal. De Gruyter Open Ltd. https://doi.org/10.2478/ebtj-2019-0006

[12] Tyczewska, A., Twardowski, T., & Woźniak-Gientka, E. (2023, March 1). Agricultural biotechnology for sustainable food security. Trends in Biotechnology. Elsevier Ltd. https://doi.org/10.1016/j.tibtech.2022.12.013

[13] Holzinger, A., Keiblinger, K., Holub, P., Zatloukal, K., & Müller, H. (2023). AI for life: Trends in artificial intelligence for biotechnology. New Biotechnology, 74, 16–24. https://doi.org/10.1016/j.nbt.2023.02.001

[14] Martin, D. K., Vicente, O., Beccari, T., Kellermayer, M., Koller, M., Lal, R., … Dundar, M. (2021). A brief overview of global biotechnology. Biotechnology and Biotechnological Equipment, 35(1), 354–363. https://doi.org/10.1080/13102818.2021.1878933

[15] Ranjha, M. M. A. N., Shafique, B., Khalid, W., Nadeem, H. R., Mueen-ud-Din, G., & Khalid, M. Z. (2022, March 1). Applications of Biotechnology in Food and Agriculture: a Mini-Review. Proceedings of the National Academy of Sciences India Section B - Biological Sciences. Springer. https://doi.org/10.1007/s40011-021-01320-4

[16] McCarty, N. S., & Ledesma-Amaro, R. (2019, February 1). Synthetic Biology Tools to Engineer Microbial Communities for Biotechnology. Trends in Biotechnology. Elsevier Ltd.https://doi.org/10.1016/j.tibtech.2018.11.002

[17] Benner, S. A., & Seymour, A. M. (2005, July). Synthetic biology. Nature Reviews Genetics. https://doi.org/10.1038/nrg1637

[18] Aminian-Dehkordi, J., Rahimi, S., Golzar-Ahmadi, M., Singh, A., Lopez, J., Ledesma-Amaro, R., & Mijakovic, I. (2023, November 1). Synthetic biology tools for environmental protection. Biotechnology Advances. Elsevier Inc. https://doi.org/10.1016/j.biotechadv.2023.108239

[19] El Karoui, M., Hoyos-Flight, M., & Fletcher, L. (2019). Future trends in synthetic biology—a report. Frontiers in Bioengineering and Biotechnology, 7(AUG). https://doi.org/10.3389/fbioe.2019.00175

[20] Amack, S. C., & Antunes, M. S. (2020, December 1). CaMV35S promoter – A plant biology and biotechnology workhorse in the era of synthetic biology. Current Plant Biology. Elsevier B.V. https://doi.org/10.1016/j.cpb.2020.100179

[21] Amado, D. A., & Davidson, B. L. (2021, December 1). Gene therapy for ALS: A review. Molecular Therapy. Cell Press. https://doi.org/10.1016/j.ymthe.2021.04.008

[22] Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023, March 1). Various AAV Serotypes and Their Applications in Gene Therapy: An Overview. Cells. MDPI. https://doi.org/10.3390/cells12050785

[23] Angela, X. M., & High, K. A. (2019, January 27). Entering the modern era of gene therapy. Annual Review of Medicine. Annual Reviews Inc. https://doi.org/10.1146/annurev-med-012017-043332

[24] Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., … Betapudi, V. (2019). Gene therapy leaves a vicious cycle. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2019.00297

[25] Uddin, F., Rudin, C. M., & Sen, T. (2020, August 7). CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2020.01387